20 articles
New research reveals how chronic inflammation varies by person, paving the way for personalized interventions to combat age-related diseases.
Discover how persistent low-grade inflammation drives the aging process and learn strategies to combat this silent threat to longevity.
A comprehensive review reveals how inflammaging—the fusion of aging and inflammation—fuels cardiovascular disease through senescence, mitochondrial dysfunction, and gut dysbiosis.
Master the molecular architecture of complement dysregulation in aging — from regulatory protein biochemistry to cutting-edge therapeutic targets — and understand how precision interventions can restore balance without dismantling immunity.
New research reveals how low-grade inflammation creates a cycle of liver damage in older adults, pointing to promising therapeutic targets.
Go beyond the basics to explore how complement pathways, regulatory failures, and senescent cells interact to drive the chronic inflammation that accelerates aging at the molecular level.
A major cross-population study finds that chronic inflammation linked to aging may reflect industrialized lifestyles, not biology alone.
BioAge's oral NLRP3 inhibitor BGE-102 cut hsCRP by ~85% in weeks, signaling a potential breakthrough in treating chronic inflammation at scale.
A mechanistic deep-dive into cutting-edge anti-inflammaging interventions — from senolytic pharmacology and precision cytokine targeting to partial reprogramming strategies that aim to restore youthful immune homeostasis.
New therapies targeting inflammation pathways could reduce cardiovascular disease and slow kidney disease progression in CKD patients.
Belgian biotech Coultreon raises $125M to advance an oral SIK3 inhibitor that rebalances inflammation rather than suppressing immunity outright.
New research links chronic low-grade inflammation to faster epigenetic aging, measured across four validated biological clocks.
New research reveals how fat-derived molecules naturally shut down inflammation, offering hope for safer arthritis and heart disease treatments.
BioAge's oral drug BGE-102 dramatically reduced hsCRP and IL-6 in obese participants with elevated inflammation, with a strong safety profile.
Senescent T cells fuel psoriasis, eczema, and rosacea through toxic secretions. New therapies may finally break the cycle.
Mendelian randomization links circulating inflammatory proteins to retinal microvascular changes, heart disease risk, and lifespan — establishing causal direction.
A landmark 2025 review maps the molecular and cellular mechanisms driving immune aging, linking inflammaging to cancer, neurodegeneration, and infection.
Revolutionary framework combines quarterly biomarker testing with AI-powered lifestyle coaching to reduce aging-related inflammation.
New research maps the connection between cellular senescence, chronic inflammation, and cardiovascular disease progression.
Go beyond inflammaging basics to understand how aging reshapes immune cell populations, triggers the SASP, and locks the body into a state of chronic low-grade inflammation at the molecular level.
